PURPOSE: To investigate the safety and efficacy of intravitreal injection of melphalan for retinoblastoma. METHODS: A retrospective chart review of all patients who were administered intravitreal injections of melphalan for retinoblastoma between 1990 and 2011. A total of 264 eyes of 250 patients were included. All ocular adverse events, systemic prognosis, ocular prognosis, and visual acuity were investigated. RESULTS: The total number of intravitreal injections administered was 1,067; each eye received between one and 25 injections. A postoperative subconjunctival tumor developed in one eye. None of the eyes suffered infections or uveitis, and all other adverse events including chorioretinal atrophy displayed incidences of less than 1.5 %. At 5 postoperative years, the cumulative incidence of cataract surgery was 3.1 % among the eyes that were treated without ocular hyperthermia. Distant metastasis or intracranial invasion occurred in 11 patients, all of whom had high-risk pathological factors for metastasis such as optic nerve invasion, but refused to receive adjuvant chemotherapy. Sixty-eight percent of the eyes achieved complete vitreous seed remission, but recurrence occurred in 19 % of these eyes after 10.0 ± 4.9 months. In addition, 47 and 27 % of the eyes without primary macular tumors retained visual acuity of >0.5 and >1.0, respectively. CONCLUSIONS: The risk of extraocular tumor spreading following intravitreal injections is low, and other adverse events are rare. Sixty-eight percent of the treated eyes achieved complete vitreous seed remission, and about half of them retained practical levels of vision. The intravitreal injection of melphalan is a safe and effective treatment for vitreous seeds.
PURPOSE: To investigate the safety and efficacy of intravitreal injection of melphalan for retinoblastoma. METHODS: A retrospective chart review of all patients who were administered intravitreal injections of melphalan for retinoblastoma between 1990 and 2011. A total of 264 eyes of 250 patients were included. All ocular adverse events, systemic prognosis, ocular prognosis, and visual acuity were investigated. RESULTS: The total number of intravitreal injections administered was 1,067; each eye received between one and 25 injections. A postoperative subconjunctival tumor developed in one eye. None of the eyes suffered infections or uveitis, and all other adverse events including chorioretinal atrophy displayed incidences of less than 1.5 %. At 5 postoperative years, the cumulative incidence of cataract surgery was 3.1 % among the eyes that were treated without ocular hyperthermia. Distant metastasis or intracranial invasion occurred in 11 patients, all of whom had high-risk pathological factors for metastasis such as optic nerve invasion, but refused to receive adjuvant chemotherapy. Sixty-eight percent of the eyes achieved complete vitreous seed remission, but recurrence occurred in 19 % of these eyes after 10.0 ± 4.9 months. In addition, 47 and 27 % of the eyes without primary macular tumors retained visual acuity of >0.5 and >1.0, respectively. CONCLUSIONS: The risk of extraocular tumor spreading following intravitreal injections is low, and other adverse events are rare. Sixty-eight percent of the treated eyes achieved complete vitreous seed remission, and about half of them retained practical levels of vision. The intravitreal injection of melphalan is a safe and effective treatment for vitreous seeds.
Authors: Carol L Shields; Fairooz P Manjandavida; Sruthi Arepalli; Swathi Kaliki; Sara E Lally; Jerry A Shields Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Scott E Brodie; Francis L Munier; Jasmine H Francis; Brian Marr; Y Pierre Gobin; David H Abramson Journal: Doc Ophthalmol Date: 2012-11-11 Impact factor: 2.379
Authors: Carol L Shields; Santosh G Honavar; Anna T Meadows; Jerry A Shields; Hakan Demirci; Arun Singh; Debra L Friedman; Thomas John Naduvilath Journal: Am J Ophthalmol Date: 2002-05 Impact factor: 5.258
Authors: Esther Eljarrat-Binstock; Abraham J Domb; Faik Orucov; Amir Dagan; Joseph Frucht-Pery; Jacob Pe'er Journal: Curr Eye Res Date: 2008-03 Impact factor: 2.424
Authors: Steven M Nguyen; Julian Sison; Marjorie Jones; Jesse L Berry; Jonathan W Kim; A Linn Murphree; Vanessa Salinas; Arthur J Olch; Eric L Chang; Kenneth K Wong Journal: Int J Radiat Oncol Biol Phys Date: 2018-12-08 Impact factor: 7.038
Authors: Matthew D Karl; Jasmine H Francis; Saipriya Iyer; Brian Marr; David H Abramson Journal: J Pediatr Ophthalmol Strabismus Date: 2017-01-17 Impact factor: 1.402
Authors: Norbert Bornfeld; Eva Biewald; Sebastian Bauer; Petra Temming; Dietmar Lohmann; Michael Zeschnigk Journal: Dtsch Arztebl Int Date: 2018-02-16 Impact factor: 5.594
Authors: Jesse L Berry; Liya Xu; A Linn Murphree; Subramanian Krishnan; Kevin Stachelek; Emily Zolfaghari; Kathleen McGovern; Thomas C Lee; Anders Carlsson; Peter Kuhn; Jonathan W Kim; David Cobrinik; James Hicks Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Jasmine H Francis; Ijah Mondesire-Crump; Brian P Marr; Scott E Brodie; David H Abramson Journal: J Pediatr Ophthalmol Strabismus Date: 2016-02-04 Impact factor: 1.402
Authors: M J Del Sole; M Clausse; P Nejamkin; B Cancela; M Del Río; G Lamas; F Lubieniecki; J H Francis; D H Abramson; G Chantada; P Schaiquevich Journal: Exp Eye Res Date: 2022-03-08 Impact factor: 3.770